Solid and liquid lipid-based binary solid lipid nanoparticles of diacerein: In vitro evaluation of sustained release, simultaneous loading of gold nanoparticles, and potential thermoresponsive behavior

International Journal of Nanomedicine

Volumn 10, Issue , 2015, Pages 2805-2814

  Rehman, Mubashar ^a   Madni, Asadullah ^a   Ihsan, Ayesha ^b   Khan, Waheed Samraiz ^b   Khan, Muhammad Imran ^a   Mahmood, Muhammad Ahmad ^a   Ashfaq, Muhammad ^a   Bajwa, Sadia Zafar ^b   Shakir, Imran ^c  

^a THE ISLAMIA UNIVERSITY OF BAHAWALPUR   (Pakistan)

^b NATIONAL INSTITUTE FOR BIOTECHNOLOGY AND GENETIC ENGINEERING NIBGE   (Pakistan)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Binary; Diacerein; Gold nanoparticles; Lipids; Nanoparticles; Thermoresponsive

Indexed keywords

DIACEREIN; DRUG CARRIER; GOLD NANOPARTICLE; LAURIC ACID; LIQUID LIPID NANOPARTICLE; OLEIC ACID; SOLID LIPID NANOPARTICLE; STEARIC ACID; UNCLASSIFIED DRUG; ANTHRAQUINONE DERIVATIVE; ANTIINFLAMMATORY AGENT; DELAYED RELEASE FORMULATION; FATTY ACID; GOLD; LIPID; METAL NANOPARTICLE; STEARIC ACID DERIVATIVE;

ARTICLE; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DOSAGE FORM COMPARISON; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; EMULSION; IN VITRO STUDY; INFRARED SPECTROSCOPY; NANOENCAPSULATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; SUSTAINED DRUG RELEASE; TEMPERATURE SENSITIVITY; THERMORESPONSIVE DRUG RELEASE; X RAY DIFFRACTION; ZETA POTENTIAL; ADMINISTRATION AND DOSAGE; CHEMISTRY; DELAYED RELEASE FORMULATION; ELECTROCHEMICAL ANALYSIS; EVALUATION STUDY; GENETIC PROCEDURES; KINETICS; METABOLISM; PROCEDURES; TEMPERATURE;

ANTHRAQUINONES; ANTI-INFLAMMATORY AGENTS; BIOSENSING TECHNIQUES; DELAYED-ACTION PREPARATIONS; DRUG DELIVERY SYSTEMS; ELECTROCHEMICAL TECHNIQUES; FATTY ACIDS; GOLD; IN VITRO TECHNIQUES; KINETICS; LIPIDS; METAL NANOPARTICLES; STEARIC ACIDS; TEMPERATURE; X-RAY DIFFRACTION;

EID: 84928138288     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S67147     Document Type: Article

References (31)

1. Myasoedova E, Cynthia SC, Hilal M, Terry MT, Sherine EG. Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955-2007. Arthritis Rheum. 2010;62:1576-1582.
2. Sanchez C, Mathy-Hartert M, Deberg MA, Ficheux H, Reginster JY, Henrotin YE. Effects of rhein on human articular chondrocytes in alginate beads. Biochem Pharmacol. 2003;65:377-388.
3. Alvarez-Soria MA, Herrero-Beaumont G, Sanchez-Pernaute O, Bellido M, Largo R. DCN has a weak effect on the catabolic pathway of human osteoarthritis synovial fibroblast - comparison to its effects on osteoarthritic chondrocytes. Rheumatology. 2008;47:627-633.
4. Maski N, Kumaran A, Girhepunje K, Ghode P, Randive S, Pal R. Studies on the preparation, characterization and solubility of β-cyclodextrin-DCN inclusion complexes. Int J Pharm Pharm Sci. 2009;1:121-135.
5. Nicolas P, Tod M, Padoin C, Petitjean O. Clinical pharmacokinetics of diacerein. Clin Pharmacokinet. 1998;35:347-359.
6. Dougados M, Nguyen M, Berdah L, Maziéres B, Vignon E, Lequesne M; ECHODIAH Investigators Study Group. Evaluation of the structure-modifying effects of DCN in hip osteoarthritis: ECHODIAH, a three-year, placebo-controlled trial. Evaluation of the chondromodulating effect of diacerein in OA of the hip. Arthritis Rheum. 2001;44:2539-2547.
7. Brahmachari B, Chatterjee S, Ghosh A. Efficacy and safety of DCN in early knee osteoarthritis: a randomized placebo-controlled trial. Clin Rheumatol. 2009;8:1193-1198.
8. European Medicine Agency. PRAC recommends suspension of diacerein-containing medicines. London, UK: European Medicine Agency Online Resources, Inc; 2013. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001947.jsp&mid=WC0b01ac058004d5c1. Accessed November 10, 2013.
9. Ramos-Zavala MG, González-Ortiz M, Martínez-Abundis E, Robles-Cervantes JA, González-López R, Santiago-Hernández NJ. Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial. Diabetes Care. 2011;34:1591-1594.
10. Mehnert W, Mäder K. Solid lipid nanoparticles. Production, characterization and applications. Adv Drug Deliv Rev. 2001;47:165-196.
11. Khalil RM, El-Bary AA, Kassem MA, Ghorab MM, Ahmed MB. Solid lipid nanoparticles for topical delivery of meloxicam: development and in vitro characterization. Presented at the Annual International Interdisciplinary Conference, April 24-26, 2013, Azores Islands, Portugal.
12. Mühlen A, Schwarz C, Mehnert W. Solid lipid nanoparticles (SLN) for controlled drug delivery - drug release and release mechanism. Eur J Pharm Biopharm. 1998;45:149-155.
13. Joh DY, Kao GD, Murty S, et al. Theranostic gold nanoparticles modified for durable systemic circulation effectively and safely enhance the radiation therapy of human sarcoma cells and tumors. Transl Oncol. 2013;6:722-731.
14. Hussain I, Hussain SZ, Habib-ur-Rehman, et al. In situ growth of gold nanoparticles on latent fingerprints - from forensic applications to inkjet printed nanoparticle patterns. Nanoscale. 2010;2:2575-2578.
15. Jenning V, Mäder K, Gohla SH. Solid lipid nanoparticles (SLN™) based on binary mixtures of liquid and solid lipids: a 1H-NMR study. Int J Pharm. 2005;205:15-21.
16. Research Unit of General Practice, Copenhagen. Implantation of gold beads to relieve discomfort from knee osteoarthritis. Bethesda, MD, USA: National Institutes of Health; 2007. Available from: http://clinicaltrials.gov/show/NCT00487370. Accessed November 23, 2014.
17. Rothenfluh DA, Bermudez H, O'Neil CP, Hubbell JA. Biofunctional polymer nanoparticles for intraarticular targeting and retention in cartilage. Nat Mater. 2008;7:248-254.
18. Yeo Y, Baek N, Park K. Microencapsulation methods for delivery of protein drugs. Biotechnol Bioprocess Eng. 2001;6:213-230.
19. Mao SR, Wang YZ, Ji HY, Bi DZ. [Preparation of solid lipid nanoparticles by microemulsion technique]. Yao Xue Xue Bao. 2003;38:624-626. Chinese.
20. Kumar PP, Gayatri P, Sunil R, Jaganmohan S, Rao YM. Atorvastatin loaded solid lipid nanoparticles: formulation, optimization, and in vitro characterization. IOSR J Pharm. 2013;2:23-32.
21. Chavda H, Patel J, Chavada G, Dave S, Patel A, Patel C. Self-nanoemulsifying powder of isotretinoin: preparation and characterization. J Powder Technol. 2013;2013:108569.
22. Clogston JD, Patri AK. Zeta potential measurement. Methods Mol Biol. 2011;697:63-70.
23. Jain A, Kumar SS, Yuvraj S, Sanjay S. Development of lipid nanoparticles of DCN, an antiosteoarthritic drug for enhancement in bioavailability and reduction in its side effects. J Biomed Nanotechnol. 2013;9:891-900.
24. Akbari B, Tavandashti MP, Zandrahimi M. Particle size characterization of nanoparticles - a practical approach. Iran J Mater Sci Eng. 2011;8:48-56.
25. Muller RH, Mader K, Gohla S. Solid lipid nanoparticle (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50:161-177.
26. Lobovkina T, Jacobson GB, Gonzalez EG, et al. In vivo sustained release of siRNA from solid lipid nanoparticles. ACS Nano. 2011;5:9977-9983.
27. Friedrich I, Reichl S, Müller-Goymann CC. Drug release and permeation studies of nanosuspensions based on solidified reverse micellar solutions (SRMS). Int J Pharm. 2005;305:167-175.
28. Collins JA, Cosh JA. Temperature and biochemical studies of joint inflammation. Ann Rheum Dis. 1970;29:386-389.
29. McAlindon T, Formica M, Schmid CH, Fletcher J. Changes in barometric pressure and ambient temperature influence osteoarthritis pain. Am J Med. 2007;120:429-434.
30. Robinson V, Brosseau L, Casimiro L, et al. Thermotherapy for treating rheumatoid arthritis. Cochrane Database Syst Rev. 2002;2:CD002826.
31. Barzegar-Jalali M, Adibkia K, Valizadeh H, et al. Kinetic analysis of drug release from nanoparticles. J Pharm Pharm Sci. 2008;11:167-177.